Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 18/20 | 0.66 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12001135 | 0.87 | ACACB (0.67) | ACACB | |
| SCHEMBL12001159 | 0.84 | ACACB (0.68) | ACACB | |
| SCHEMBL255708 | 0.83 | ACACB (0.53) | ACACB | |
| SCHEMBL12001468 | 0.82 | ACACB (0.69) | ACACB | |
| SCHEMBL255712 | 0.81 | ACACB (0.66) | ACACB | |
| SCHEMBL12001203 | 0.80 | ACACB (0.72) | ACACB | |
| SCHEMBL12001511 | 0.80 | ACACB (0.67) | ACACB | |
| SCHEMBL256150 | 0.80 | ACACB (0.67) | ACACB | |
| SCHEMBL12001713 | 0.80 | ACACB (0.67) | ACACB | |
| SCHEMBL12001150 | 0.80 | ACACB (0.67) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214785-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214785-A1 | New compounds, pharmaceutical compositions and uses thereof | ABCG2, PGA5, PDE6G | ACACB 2257/4885MAPK8 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.